BY13
BY13 is a SRC-3 PROTAC degrader with a DC50 of 0.031 μM. BY13 selectively blocks the ER signaling pathway over that of androgen receptor (AR) ) through down-regulating ERα level. BY13 potently overcomes endocrine resistance in breast cancer by inducing cell cycle arrest in G1 phase and apoptosis, with superior effect over Fulvestrant (HY-13636) . BY13 significantly inhibits the growth of drug-resistant breast tumors without obvious toxicity in LCC2 xenograft mice model[1]. Pink: SRC-3 ligand (SI-2) (HY-101447) ; Blue: CRBN ligase ligand (HY-41547) ; Black: linker (HY-176226)
Product Specifications
UNSPSC
12352005
Target
Apoptosis; Estrogen Receptor/ERR; PROTACs; Src
Related Pathways
Apoptosis; PROTAC; Protein Tyrosine Kinase/RTK; Vitamin D Related/Nuclear Receptor
Field of Research
Cancer
Smiles
C/C(C1=NC=CC=C1)=N\NC2=NC(C=CC=C3)=C3N2C4CN(C4)C5CCN(CC5)C6=CC=CC7=C6C(N(C7=O)C8C(NC(CC8)=O)=O)=O
Molecular Formula
C35H35N9O4
Molecular Weight
645.71
References & Citations
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
ERα; SRC-3
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
Recombinant Staphylococcus aureus HTH-type transcriptional regulator sarV (sarV)
Recombinant Staphylococcus aureus HTH-type transcriptional regulator sarV (sarV)
Recombinant Staphylococcus aureus HTH-type transcriptional regulator sarV (sarV)
Recombinant Staphylococcus aureus HTH-type transcriptional regulator sarV (sarV)
Recombinant Staphylococcus aureus HTH-type transcriptional regulator sarV (sarV)